Home Biosimilar Antibodies Others Others Naratuximab (Anti-TSPAN26 / CD37)
For research use only. Not for use in humans.

Naratuximab (Anti-TSPAN26 / CD37)

Synonyms: CD37,Tspan-26

Naratuximab (Anti-TSPAN26 / CD37) is a humanized monoclonal antibody targeting CD37 (TSPAN26). It can be used to synthesize an ADC compound, naratuximab emtansine which is used in treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). MW : 150 KD.

Naratuximab (Anti-TSPAN26 / CD37)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 6.37mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Naratuximab (Anti-TSPAN26 / CD37) is a humanized monoclonal antibody targeting CD37 (TSPAN26). It can be used to synthesize an ADC compound, naratuximab emtansine which is used in treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). MW : 150 KD.
References

Product Details

CAS No. 1622327-39-2
Molecular Weight 150
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07220616 RECRUITING Drug: DS3790a|Drug: Combination drug|Drug: Combination drug Hematological Malignancies; B-cell Non-Hodgkin Lymphoma Daiichi Sankyo 2026-01-16 PHASE1; PHASE2
NCT04136275 COMPLETED Hematologic Malignancy; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin Marcela V. Maus, M.D.,Ph.D. 2020-06-19 PHASE1
NCT04358458 TERMINATED Diffuse Large B-cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma Genmab 2020-03-13 PHASE1; PHASE2
NCT00614042 COMPLETED Drug: TRU-016 (anti-CD37 protein therapeutic) Chronic Lymphocytic Leukemia (CLL); Non-Hodgkin's Lymphoma (NHL) Aptevo Therapeutics 2008-01 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-08-24)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.